Join scPharmaceuticals for a KOL webinar focused on a nephrologist’s perspective on the use of FUROSCIX for treating fluid overload in heart failure and the potential use in chronic kidney disease (CKD). The event will feature Dr. Michael Aaronson, MD (Lincoln Nephrology and Hypertension, Lincoln, NE)

The FDA has assigned a PDUFA target action date of March 6, 2025, to consider scPharmaceuticals’ Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include chronic kidney disease.

scPharmaceuticals’ management will also provide a corporate update focused on the company’s long-term growth initiatives, including the FDA-approved expansion of the FUROSCIX indication to include New York Heart Association (NYHA) Class IV heart failure patients, the potential expansion of the FUROSCIX indication to include treatment of fluid overload in CKD patients, and the ongoing development of a low volume autoinjector designed to provide physicians and patients with additional treatment flexibility.

A live question and answer session will follow the formal presentation.